hims stock has fallen for the third day in a row as investors brace for a key FDA advisory committee meeting set for July 23 24, 2026. This federal panel will examine seven unapproved peptides that could significantly influence the regulatory landscape for compounding pharmacies, a sector closely tied to Hims & Hers Health's business.
The stock dropped to $32.7 on July 21, slipping 0.4% that day alone, reflecting growing market caution. Adding to the unease, Hims’ CFO Oluyemi Okupe sold 7,163 shares on July 18 at roughly $32 per share, netting about $229,000. These shares came from options exercised earlier the same day at a strike price of $5.01, a detail that has drawn extra attention from investors.
The FDA’s Pharmacy Compounding Advisory Committee will review peptides including BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax, and TB-500. A positive ruling could pave the way for compounding pharmacies to legally prepare these substances under Section 503A guidelines. However, preliminary FDA staff reports express skepticism, citing limited human clinical data and unresolved safety issues like immune reactions and contamination risks.
In response to earlier critiques about conflicts of interest, the agency expanded the committee by adding eight new voting members, many of whom are seen as more impartial and better qualified. Some members will only vote on specific peptides, aiming to ensure a more transparent and focused review.
Regulatory uncertainty remains the key driver behind recent price movements for hims stock. The outcome of this meeting could reshape the company’s clinical and financial trajectory significantly.
